Unveiling the Potential of ProstateSpecific Membrane Antigen for Precision Diagnosis and Therapy of Prostate Cancer: A Radiopharmaceutical Perspective
Authors:
- Universiti Putra Malaysia Centre For Diagnostic Nuclear ImagingUIUniversiti Putra Malaysia Centre For Diagnostic Nuclear Imaging
- Hishar HassanHHHishar Hassan
- 27 August 2024
- journal article
- research article
- Published by Penerbit Universiti Sains Malaysia in Malaysian Journal of Medical Sciences
- Vol. 31 (4) , 213-217
Abstract
Prostate-specific membrane antigen (PSMA) has proven to be an important target for diagnostic imaging in prostate cancer. As PSMA is overexpressed on the surface of prostate cancer cells, numerous targeted PSMA ligands have been developed. The emergence of PSMA targeting based on small molecules, such as the PSMA-11 ligand (or PSMA-HBED-CC), has led to breakthroughs, such as [68Ga]Ga-PSMA-11, for positron emission tomography (PET) imaging of biochemically recurrent or metastatic castration-resistant prostate cancer (mCRPC). In addition, the recent approval of [177Lu]Lu-PSMA-617 for the treatment of adult patients with PSMA-positive mCRPC represents an important milestone in prostate cancer therapy. These advances underscore the growing confidence in the use of PSMA-targeted radiopharmaceuticals for the diagnosis and treatment of prostate cancer patients. PSMA-targeted radiopharmaceuticals have been shown to significantly impact treatment planning and clinical decision-making and facilitate the customisation of treatment regimens.Keywords
This publication has 12 references indexed in Scilit:
- PSMA-Targeting Imaging and Theranostic Agents—Current Status and Future PerspectiveInternational Journal of Molecular Sciences, 2022
- Prostate cancer in multi‐ethnic Asian men: Real‐world experience in the Malaysia Prostate Cancer (M‐CaP) StudyCancer Medicine, 2021
- Recent trend of androgen deprivation therapy in newly diagnosed prostate cancer patients: Comparing between high‐ and middle‐income Asian countriesCancer Science, 2021
- Prostate-specific membrane antigen (PSMA)–ligand positron emission tomography and radioligand therapy (RLT) of prostate cancerJapanese Journal of Clinical Oncology, 2020
- (Radio)Theranostic Patient Management in Oncology Exemplified by Neuroendocrine Neoplasms, Prostate Cancer, and Breast CancerPharmaceuticals, 2020
- Biological principles and clinical application of positron emission tomography-tracers in prostate cancer: a reviewProstate International, 2019
- Diagnostic Efficacy of 68 Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate CancerJournal of Urology, 2016
- Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancerEJNMMI Research, 2014
- The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2014
- Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis.2005